8 February 2019

TIKOMED successfully closed fundraising of 8 Million Euros

Viken – 8th February 2019 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced its successful completion of the company’s latest fundraising of 8 Million Euros to support the ongoing clinical development program for both the ILB-program and the IBsolvMIR® program.

TIKOMED is developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases (ILB program) and an infusion product for improving outcomes in cell therapies (IBsolvMIR® program).

“I’m delighted that we have successfully completed our latest fundraising, which demonstrate both the level of interest and trust in our clinical program from investors”, said Anders Kristensson, CEO of TIKOMED.

DATE
TBA

TIME
TBA

VENUE
TBA

OTHER NEWS

6 February 2019
Shadow Lake Group appointed Strategic Advisor and Business Development representative for the licensing process of IBsolvMIR® in Canada
Viken – 6th February 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced…
Read More
30 November 2018
TIKOMED Granted Permission for Phase 2 Clinical Trial in Islet Cell Transplantation by the Swedish Medical Product Agency
VIKEN, Sweden, November 19, 2018 (Newswire) -TIKOMED, a specialty pharmaceutical company developing IBsolvMIR, an infusion…
Read More
2 November 2018
First patient treated with ILB in TIKOMED’s clinical trial for ALS
Viken, November 2nd, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for…
Read More
SEE MORE